8-K: HeartSciences Inc. Amends Bylaws to Include Jury Trial Waiver and 3% Shareholder Threshold for Derivative Lawsuits

HeartSciences Inc. has amended its bylaws to introduce a jury trial waiver for internal entity claims and establish a 3% ownership threshold for shareholders to initiate derivative proceedings, effective June 27, 2025.

Summary

• HeartSciences Inc.'s Board of Directors adopted amendments to its Bylaws on June 27, 2025.
• The amendments include a new section providing for a jury trial waiver for "internal entity claims" as defined in the Texas Business Organizations Code (TBOC).
• A new section was added requiring any shareholder or group of shareholders to hold at least 3% of the company's issued and outstanding common shares to institute or maintain a derivative proceeding.
• Technical revisions were made to clarify the scope of the exclusive forum provision, designating the Texas Business Court in Dallas County, Texas, or the United States District Court for the Northern District of Texas, as the exclusive forum for certain internal entity claims.
• These amendments were adopted in accordance with Texas law and became effective on June 27, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the amendments significantly limiting shareholder rights and increasing the difficulty for shareholders to pursue legal recourse or hold management accountable through derivative actions. While aligning with state law is positive, the specific provisions regarding jury trial waivers and high ownership thresholds for derivative suits are generally viewed unfavorably by shareholder advocates.

Positives

• Alignment of bylaws with recent changes to the Texas Business Organizations Code (TBOC) ensures legal compliance and updated corporate governance.
• Clarification of the exclusive forum provision may centralize litigation, potentially reducing legal costs and complexities for the company.

Negatives

• The introduction of a jury trial waiver for internal entity claims limits shareholders' legal recourse and may be perceived as reducing shareholder protections.
• Establishing a 3% ownership threshold for derivative proceedings significantly increases the barrier for individual shareholders or smaller groups to initiate lawsuits on behalf of the company, potentially hindering corporate accountability.

Risks

• Increased difficulty for minority shareholders to hold management accountable due to the 3% ownership threshold for derivative proceedings.
• Potential for reduced shareholder oversight and increased management discretion due to limitations on legal avenues.
• Shareholder dissatisfaction or legal challenges regarding the new bylaw provisions, particularly the jury trial waiver and derivative action threshold.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on corporate governance amendments.

Management Comments

• The filing was signed by Danielle Watson, Chief Financial Officer, indicating the company's official communication of the bylaw amendments.

Industry Context

The amendments reflect a broader trend among U.S. corporations, particularly those incorporated in states like Texas and Delaware, to adopt bylaws that centralize litigation and limit shareholder litigation avenues, such as derivative actions and jury trials. This is often done to streamline legal processes and reduce potential litigation costs, though it can be viewed critically by shareholder advocacy groups.

Comparison to Industry Standards

• Jury trial waivers in corporate bylaws are a growing trend, particularly following a 2014 Delaware Supreme Court ruling that upheld such waivers for internal corporate claims. While not universally adopted, they are becoming more common in corporate charters and bylaws, especially in states with business-friendly legal frameworks like Texas.
• Shareholder ownership thresholds for derivative lawsuits vary significantly. A 3% threshold is on the higher side compared to some jurisdictions or common law standards, which often allow any shareholder to bring a derivative suit, or require a lower percentage (e.g., 1% or less) or a demonstration of continuous ownership. This higher threshold could be seen as more restrictive than the average for publicly traded companies.
• Exclusive forum provisions are widely adopted by U.S. public companies, often designating the state of incorporation as the primary venue for internal corporate disputes. The clarification of the exclusive forum to the Texas Business Court or the Northern District of Texas aligns with this trend, aiming to prevent multi-forum litigation.

Corporate Governance

Stakeholder Impact

• Shareholders: The amendments significantly impact shareholders by limiting their ability to pursue certain legal claims (jury trial waiver) and increasing the threshold for initiating derivative lawsuits (3% ownership), potentially reducing their oversight and legal recourse against management.
• Management/Board of Directors: The changes provide greater protection against shareholder litigation, potentially reducing legal risks and costs associated with internal entity claims and derivative actions.
• Creditors, Employees, Suppliers, Customers: No direct impact on these stakeholders is indicated by the bylaw amendments.

Next Steps

• The document does not specify any immediate future actions or milestones resulting directly from these bylaw amendments.

Key Dates

Recommendation

Keywords

HeartSciences Inc., HSCS, Bylaw Amendments, Corporate Governance, SEC Filing, 8-K, Jury Trial Waiver, Derivative Proceedings, Shareholder Rights, Texas Business Organizations Code, Exclusive Forum, Corporate Law